(NASDAQ)
7.11
+0.17   (+2.02%)
 
Volume (24h) Market Cap. Day Range 52w Range
69,574 187.96M 6.85 - 7.30 2.40 - 7.60
Jan-27-21 09:00AM Oramed Issues Letter to ShareholdersPR Newswire
Jan-21-21 08:25AM Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin StudyPR Newswire
Jan-08-21 05:19AM We're Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash WiselySimply Wall St.
Jan-07-21 08:40AM Oramed to Present at H.C. Wainwright BioConnect 2021 ConferencePR Newswire
Dec-23-20 08:25AM Oramed Reports Positive First in Human Data from Oral Leptin StudyPR Newswire
Dec-10-20 08:05AM ORMP: ORMD-0801 in Phase 3 TD2 and NASH Clinical StudiesZacks Small Cap Research
Dec-03-20 09:05AM Is Oramed Pharmaceuticals (ORMP) A Good Stock To Buy Now?Insider Monkey
Dec-02-20 08:25AM Oramed Initiates Phase 2 NASH Trial of Oral InsulinPR Newswire
Nov-24-20 08:10AM Oramed Initiates Phase 3 Trial of Oral InsulinPR Newswire
Nov-12-20 08:40AM Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020PR Newswire
Nov-10-20 08:25AM Oramed to Present at H.C. Wainwright 6th Annual Israel ConferencePR Newswire
Nov-09-20 12:26PM Oramed Pharmaceuticals'(NASDAQ:ORMP) Share Price Is Down 71% Over The Past Three Years.Simply Wall St.
Oct-28-20 08:40AM Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 ConferencePR Newswire
Oct-27-20 08:55AM Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020PR Newswire
Oct-16-20 08:40AM Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDAPR Newswire
Sep-22-20 07:12AM ORMP: Advancing Toward Phase 3 Program For ORMD-0801Zacks Small Cap Research
Sep-21-20 08:25AM Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual MeetingPR Newswire
Sep-15-20 08:25AM Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and PatientsPR Newswire
Sep-03-20 08:10AM Oramed to Present at H.C. Wainwright Global Investment ConferencePR Newswire
Aug-11-20 12:20PM How Much Is Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) CEO Getting Paid?Simply Wall St.
Jul-16-20 10:19AM Company News for Jul 16, 2020Zacks
Jul-15-20 08:55AM Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral InsulinPR Newswire
Jul-08-20 06:09AM Insulin in Pill Form Would Be a Bonanza for OramedGuruFocus.com
Jun-19-20 05:34AM ORMP: Positive Takeaways of Preliminary NASH Study FindingsZacks Small Cap Research
Jun-15-20 08:25AM Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral InsulinPR Newswire
Jun-09-20 07:03AM Newsflash: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Analysts Have Been Trimming Their Revenue ForecastsSimply Wall St.
Jun-04-20 06:59AM Oramed Pharmaceuticals Inc. (ORMP): Are Hedge Funds Right About This Stock?Insider Monkey
May-05-20 09:22AM Will Oramed Pharmaceuticals (NASDAQ:ORMP) Spend Its Cash Wisely?Simply Wall St.
07:55AM Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in JunePR Newswire
Apr-14-20 07:10AM ORMP: Second quarter financial results; Strengthens Advisory Board; Positive EoP2 meeting with the FDAZacks Small Cap Research
Apr-07-20 07:40AM Oramed Patent in Canada Allowed for Oral Delivery of ProteinsPR Newswire
Apr-01-20 08:40AM Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19PR Newswire
Mar-30-20 09:01AM Does Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Have A Particularly Volatile Share Price?Simply Wall St.
Mar-19-20 08:40AM Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDAPR Newswire
Mar-11-20 06:30AM ORMP: Oramed announces positive results from cohort 2 of Phase 2 trial with ORMD-0801 in T2D patientsZacks Small Cap Research
Feb-27-20 09:15AM Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 MillionPR Newswire
07:35AM The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo TherapyBenzinga
Feb-26-20 04:05AM Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common StockPR Newswire
08:00AM Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin TrialPR Newswire
Feb-12-20 09:42AM Have Insiders Been Buying Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares This Year?Simply Wall St.
Feb-04-20 08:25AM Oramed to Present at BIO CEO & Investor ConferencePR Newswire
Jan-30-20 07:25AM Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory BoardPR Newswire
Jan-28-20 07:25AM Oramed Patent in Europe to be Granted for Oral Delivery of ProteinsPR Newswire
Jan-23-20 08:00AM Oramed Elects Dr. Alexander Fleming to Scientific Advisory BoardPR Newswire
Jan-21-20 07:25AM Oramed Appoints Dr. Jay Skyler to Scientific Advisory BoardPR Newswire
Jan-09-20 07:00AM Oramed Pharmaceuticals Issues Letter to ShareholdersPR Newswire
Jan-07-20 11:38AM Does Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Pay Compare Well With Peers?Simply Wall St.
08:00AM ORMP: Multiple Data Readouts on the Horizon…Zacks Small Cap Research
Dec-22-19 06:17AM Hedge Funds Have Never Been This Bullish On Oramed Pharmaceuticals Inc. (ORMP)Insider Monkey
Dec-05-19 09:12AM Oramed Appoints Dr. Arie Mayer to Board of DirectorsPR Newswire
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Cap:    |  Volume (24h):